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Abstract
Background: The ISAR study is a prospective, longitudinal, observational cohort study to improve the cardiovascular
risk stratification in endstage renal disease (ESRD). The major goal is to characterize the cardiovascular
phenotype of the study subjects, namely alterations in micro- and macrocirculation and to determine
autonomic function.
Methods/design: We intend to recruit 500 prevalent dialysis patients in 17 centers in Munich and the
surrounding area. Baseline examinations include: (1) biochemistry, (2) 24-h Holter Electrocardiography (ECG)
recordings, (3) 24-h ambulatory blood pressure measurement (ABPM), (4) 24 h pulse wave analysis (PWA) and
pulse wave velocity (PWV), (5) retinal vessel analysis (RVA) and (6) neurocognitive testing. After 24 months
biochemistry and determination of single PWA, single PWV and neurocognitive testing are repeated. Patients
will be followed up to 6 years for (1) hospitalizations, (2) cardiovascular and (3) non-cardiovascular events and
(4) cardiovascular and (5) all-cause mortality.
Discussion/conclusion: We aim to create a complex dataset to answer questions about the insufficiently
understood pathophysiology leading to excessively high cardiovascular and non-cardiovascular mortality in
dialysis patients. Finally we hope to improve cardiovascular risk stratification in comparison to the use of
classical and non-classical (dialysis-associated) risk factors and other models of risk stratification in ESRD
patients by building a multivariable Cox-Regression model using a combination of the parameters measured
in the study.
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Background
Chronic kidney disease, in particular ESRD is associated
with a very high cardiovascular morbidity and mortality [1].
As access to dialysis is getting easier and the spectrum of
patients suitable for dialysis has broadened, the worldwide
use of renal replacement therapy (RRT) is expected to rise
significantly in the next years [2]. The life expectancy of
ESRD is similar to metastatic cancer disease. For example
the overall life expectancy of a patient after initiation of dia-
lysis is 8 years in the age group of 40 to 44 years, compared
to 30 to 40 years of life expectancy in the general popula-
tion [3]. Despite recent advances in the field of dialysis
technique [4] and insights into the complex pathophysi-
ology [5] of the changes in ESRD patients, we are far from
understanding the disease and even further from having a
cure. To understand the complex processes happening in
ESRD, we need a comprehensive characterization of the
cardio- and cerebrovascular system as the major events and
causes of mortality are of cardio-/cerebrovascular nature.
Based on these findings we hope to gain a better insight
into the pathophysiological processes happening in ESRD
and to identify new risk factors and improve risk stratifica-
tion. With introducing the ISAR study we try to shape the
most complex cardiovascular image of the patient, which
can be derived from easy and inexpensive measurements.
Thus, the methods used in this study could be easily
adapted for routine use in dialysis centers worldwide. Over-
all, we want to establish a cohort that reflects the current
medium age of dialysis patients in western countries, as we
know that dialysis patients get older. Previous studies in-
cluded patients roughly 10 years younger than the patients
we treat today and no special consideration of particular
habitats were reported. Here we report the rationale and
the study design of the ISAR study. We describe (1) cross-
sectional and prospective study objectives, (2) the methods
that will be used in the study and (3) the rationale for
choosing these methods.
Study objectives
Therefore, we aim to (1) record a cross-sectional and lon-
gitudinal picture of the vascular bed to identify and follow
changes in the vasculature and (2) to improve cardiovas-
cular (CV) and non-cardiovascular (non-CV) risk stratifi-
cation by following the patients for up to 72 months and
recording events. We intend to establish an end stage
renal disease cohort of more than 500 patients in Munich
city and surrounding area (urban vs. rural) to get an idea
of the dialysis patients treated today in Germany which
should be comparable with large parts of Europe.
The main goals of the ISAR study are:
(1)A cardio/-cerebrovascular characterization of a
representative ESRD cohort (cross-sectional and
longitudinal)
(2)To find associations between novel and established
risk factors and cardiovascular disease to get a better
mechanistic insight into the pathophysiology of
cardiovascular and infectious disease in dialysis
patients
(3)To follow cardiovascular changes over time (arterial
stiffness, central hemodynamics, cardiovascular events)
(4)To find new and established risk factors for the
prediction of morbidity and mortality (cardiovascular,
non-cardiovascular (dialysis-associated))
(5)To find associations between neurocognitive scores/
testing and end organ damage, cardiovascular risk
factors and vascular parameters
(6)To establish a serum sample database for the
discovery of novel biomarkers in ESRD
(7)To develop a robust model to predict cardiovascular
morbidity and mortality and death of all causes in a
multivariable Cox-regression analysis
We focus on the above mentioned objectives as we have
identified them as improvable areas of interest in previous
landmark studies, because the problem has either (1) not
been addressed before, (2) the population was too small or
(3) the baseline characteristics/epidemiology of the popu-
lation has changed over time, so it is not representative
for the actual population of dialysis patients taken care of
in dialysis centers in western countries any longer. Fur-
thermore, we seek to develop a combined model of the
different risk stratification methods (ABPM, PWA, PWV,
autonomous dysfunction, RVA) to improve prediction of
cardiovascular and non-cardiovascular events.
In the following, we give an overview of research ques-
tions that we want to address after establishment of the
planned dataset.
Ambulatory and office/dialysis blood pressure monitoring
(ABPM)
Objectives with cross-sectional results
(1)Build a 24-h ABPM reference database for a well-
defined dialysis cohort of prevalent dialysis patients
that are comparable to the current dialysis popula-
tion treated in European countries
(2)Evaluate the incidence of masked, white coat
hypertension and dialysis treatment associated
hypertension by comparison of pre- and post-dialysis
BP measurements with ABPM recordings
(3)Evaluate the frequency of nocturnal hypertension
(4)Find associations between 24-h ABPM measure-
ments and target organ damage
(5)Find associations between 24-h ABPM measure-
ments and other cardiovascular parameters e.g. ret-
inal vessel diameter, autonomic dysfunction, central
hemodynamics and cardiovascular risk factors
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(6)Evaluate the adherence of dialysis patients to the
prescription of 24-h ABPM (% unwillingness to par-
ticipate in ABPM, time of measurement, number of
canceled examinations, time to cancelation)
Objectives with longitudinal results
(1)Does 24-h ABPM predict
a. All-cause mortality
b. Cardiovascular mortality
c. Death from infection




(2)Compare the predictive value of intradialytic BP
measurements with 24-h ABPM
Pulse wave analysis
Objectives with cross-sectional results
(1)Establish a reference database for end stage renal disease
patients in terms of central blood pressure values
(2)Correlate measures of central hemodynamics with
end organ damage
(3)Find associations between cardiovascular risk factors
and measures of central hemodynamics
(4)Find associations between volume depletion within
the dialysis session and changes in central
hemodynamics
Objectives with longitudinal results
(1)Does 24-h PWA predict
a. All-cause mortality
b. Cardiovascular mortality
c. Death from infection




(2)Compare the predictive value of intradialytic PWA
measurements with 24-h PWA
(3)Evaluate longitudinal changes in PWA
Pulse wave velocity (derived mathematically from PWA
measurements)
Objectives with cross-sectional results
(1)Establish a reference database for PWV in an end
stage renal disease cohort
(2)Correlate PWV with end organ damage
(3)Find associations between PWV and other
cardiovascular and functional variables (e.g. retinal
vessel parameters, cardiovascular risk factors,
inflammatory biomarkers, neurocognitive score)
(4)Associate PWV with end organ damage
Objectives with longitudinal results
(1)Does 24-h PWV predict
a. All-cause mortality
b. Cardiovascular mortality
c. Death from infection




(2)Compare the predictive value of intradialytic PWA
measurements with 24-h PWV
(3)Evaluate the progression of arterial stiffness overtime
Static and dynamic retinal vessel analysis (RVA)
Objectives with cross-sectional results
(1)Evaluate the feasibility of this method in dialysis
centers and a dialysis cohort (% inclusion, technical
feasibility…)
(2)Establish a reference database for static and retinal
vessel parameters in an end stage renal disease
cohort and compare these with normal controls
(controls already available for analysis)
(3)Correlate RVA parameters (static and dynamic) with
end organ damage
(4)Find associations between static and dynamic retinal
vessel variables and other cardiovascular and
functional variables (cardiovascular risk factors,
inflammatory biomarkers, neurocognitive score,
central hemodynamics)
Objectives with longitudinal results
(1)Does static or dynamic RVA predict
a. All-cause mortality
b. Cardiovascular mortality
c. Death from infection





Objectives with cross-sectional results
(1)Evaluate the feasibility of this method in dialysis
centers and a dialysis cohort (% inclusion, technical
feasibility, % of data sets reaching the quality to be
included in the analysis)
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(2)Calculate the prevalence of atrial fibrillation (first
detected, paroxysmal, persistent, permanent) over 24 h
(3)Determination of autonomic dysfunction with linear and
non-linear methods and association of these parameters
with end organ damage and cardiovascular risk factors
(4)Evaluate the data set for new determinants of
cardiac autonomic dysfunction
(5)Calculate ECG parameters of hypertrophy and
associate with end organ damage
(6)Evaluate for arrhythmias other than atrial fibrillation
(ventricular tachycardia, ventricular extra systole,
supraventricular extra systole)
(7)Evaluate basic ECG parameters (QRS duration, QT
time, PR time, resting heart rate)
(8)Find associations between volume depletion within
the dialysis session and changes in heart rhythm
(arrhythmias including atrial fibrillation)
Objectives with longitudinal results









Objectives with cross-sectional results
(1)Evaluate the feasibility of neurocognitive testing in a
dialysis setting
(2)Evaluate the prevalence of cognitive impairment and
dementia
(3)Associate neurocognitive scores with end organ
damage and cardiovascular risk factors
(4)Associate vascular parameters (retinal vessel analysis
for microcirculation, PWA and PWV for large
vessels) with neurocognitive scores
Objectives with longitudinal results




c. Death from infection




(2)Evaluate the progression of neurocognitive decline
Cardiovascular risk stratification
After evaluation of the above data sets and risk stratifi-
cation by single estimators we aim at building a multi-
variable Cox-Regression model which will include up to
15 variables depending on the number of cardiovascular
events recorded throughout the observation period and
the true number of recruited patients (see section on
sample size and statistical analysis).
Methods and design
Substantial requirements for the selection of technical
examinations of the cardiovascular system were that
they had to be (1) well validated, (2) feasible in daily
practice and (3) cost efficient to allow use in a broad set
of patients. What methods did fulfill the above men-
tioned criteria? The steering committee decided to use
(1) 24-h Holter ECG, (2) 24-h ABPM and (3) retinal ves-
sel analysis (RVA), as these methods give an excellent
estimate of the situation in the macro- and microcircula-
tion and all methods have been very well validated in
the last years. As functional parameter of cerebrovas-
cular microcirculation we aim to measure in parts of
the cohort the neurocognitive status by Montreal
Cognitive Assessment (MoCA) and Clinical Dementia
Rating (CDR).
Study design
The ISAR study is planned as a prospective, strictly ob-
servational cohort study conducted in dialysis centers in
Munich and the greater Munich area (17 study sites).
The Ethics Committee of the Klinikum rechts der Isar of
the Technical University Munich and the ethics
Committee of the Bavarian State Board of Physicians ap-
proved the study protocol. Informed consent is obtained
from all patients. An overview of the examinations and
follow up appointments can be found in Table 1.
Blood specimen collection
All blood samples (serum and EDTA) are taken before a
midweek dialysis session. Before taking blood samples,
patients are screened for clinical infection, and those
with active infection are examined at a later time point.
Blood is sampled in serum and EDTA tubes. Serum
tubes are centrifuged. Serum is split into aliquots and
frozen at −80 °C. EDTA samples are frozen without fur-
ther processing allowing later DNA extraction. Routine
serum chemistry examinations are performed in ISO
certified laboratories in the different centers.
Screening and eligibility
All patients are reviewed by an ISAR study investigator
in the dialysis center for the following inclusion and
exclusion criteria:
Inclusion criteria
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(1)age ≥18 years
(2)dialysis vintage ≥90 days
(3)willingness to participate in at least one technical
examination (either ABPM, 24 hour Holter ECG
or RVA)
(4)written and informed consent.
We plan to recruit a control arm with patients not
willing to participate in any technical examination to
control for a bias in patient selection, in terms of the
possibility that healthier and younger patients are more




(3)malignant disease having a life expectancy of less
than 24 months
(4)lack of written and informed consent.
Study procedures/measurements
Measurements are performed in incident dialysis patients
recruited in one center after the other. The study subjects
examinations are performed in the following order: 1) in-
formed consent, 2) measurement of basic clinical data
after review of the patient charts, 3) blood samples are
taken before the midweek dialysis session, 4) start of 24-h
ECG and 24-h ABPM shortly before a midweek dialysis
session, 5) retinal vessel analysis before a midweek dialysis








T 24 months T 6y
Interviewer/Questionaires
Informed consent X
contact information X X X
sociodemographic X X X
Education and employment X X X
Vascular access X X X
Residual kidney function X X X
Dialysis prescription X X X
medical history X X X
cardiovascular risk factors X X X
Family history of CVD X X X
history of prior transplantations X X X
Physical activity X X X
MOCA X X X
CDR X X X
Restless legs score X X X
Oral medications X X X
Examination
Height, weight, BMI, upper arm
circumference
X X X
Blood pressure X X X
Procedures
12-lead holter ECG (24h) X




Pulse wave analysis (single
measurement)
X X
Pulse wave velocity (24h) X







Blood tests (prior to dialysis, fasting), midweek dialysis session
Serum blood sampling









cardiovascular events X X
cardiovascular mortality X X
Table 1 Schedule of measurements and activities by visit for
the ISAR study (Continued)
total mortality X X
dialysis routine blood work (quarterly)
Glucose, albumin X X X
complete blood count X X X
Electrolytes (Na, K, Mg, Ca, Phos) X X X
Blood gas analysis X X X
intact PTH X X X
Iron status X X X
Kt/V X X X
Dialysis treatments




Pre- and Post weights X X X
Dialysis flow rates X X X
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session 6) neurocognitive testing before dialysis in a separ-
ate room [6]. The study measurements are performed in
each center by the same observers. All observers are
trained intensively before patient examination.
ABPM and pulse wave analysis
The 24-h ABPM and parameters of arterial wall stiffness or
their surrogates (e.g., augmentation index (Aix)) are both
recorded in the same time period (24 h) using the
oscillometric device, Mobil-O-Graph (IEM, Stolberg,
Germany) with integrated ARCSolver algorithms (AIT
Austrian Institute of Technology, Vienna, Austria) [7, 8].
The Mobil-O-Graph ambulatory BP monitoring device is a
very well established and validated device as well for per-
ipheral blood pressure recording [9] and 24-h pulse wave
analysis [10–12], also for ESRD patients [13–15]. The
classical BP measuring unit in the device has been validated
according to the recommendations of the British and
European Societies of Hypertension (BHS and ESH) [9, 16].
The method, equipped with a generalized transfer function
(GTF) to derive aortic pressure waveforms, is based on
brachial readings acquired in the course of the conventional
pressure measurement at the diastolic level [7].
Surrogate parameters of central hemodynamics de-
rived by this technique have been validated against the
validation gold standard of intra-aortic catheter measure-
ments and have been compared with well-established,
non-invasive readings (e.g., tonometry, echocardiography
and magnetic resonance imaging [17]) for aortic pressures,
wave reflections [8] or aPWV [11]. Clinical usefulness of
this method has been demonstrated recently [18]. Further-
more, feasibility [10] and reproducibility [7] of cuff-based
Pulse Wave Analysis (PWA) measurements have been re-
ported. The Mobil-O-Graph PWA monitor with inte-
grated ARCSolver algorithms holds approvals from CE,
FDA and JPAL.
Static and dynamic retinal vessel analysis
Measurement with the static retinal vessel analyzer
(RVA) Using a non-mydriatic retinal camera Topcon
NW200 (Topcon, Japan), 30° color retinal photographs
of each subject were taken and analyzed by means of
Visualis and Vessel Map Software (IMEDOS Systems
Ltd., Jena, Germany). The diameters of retinal arterioles
and venules are measured as described previously [19]
and combined into summary indices [20] – the central
retinal arteriolar (CRAE) and venular equivalents
(CRVE) – which represent the average arteriolar and
venular diameters of that eye, respectively. These are
additionally expressed as the retinal arteriolar-venular
ratio (AVR). The ratio compensates for possible magnifi-
cation differences between eyes, and an AVR of 1 indi-
cates that arteriolar diameters are, on average, the same
as venular diameters in that eye, while a smaller ratio
suggests narrower arterioles. AVR < 0.7 has been shown
to be associated with microvascular disorder of different
kind [21]. This technique has been shown to be highly
reproducible [19, 22, 23] and it can be successfully used
as a “population screening tool” [21].
Measurements with the Dynamic RVA Twenty mi-
nutes after pupil dilation with topical tropicamide drops
(Mydriaticum Stulln; Pharma Stulln, Stulln, Germany)
continuous simultaneous measurements of retinal vessel
diameters of arterial and venous segments are performed
in a randomly chosen eye of a subject using a standard
protocol of Dynamic Vessel Analyzer (DVA, IMEDOS
Systems, Jena, Germany). This protocol consists of 50 s
baseline following by 3 cycles consisting of 20 s of flick-
ering light (12.5 Hz, 530 nm), 80 s constant illumination
each. Vessel segments of approximately 1 mm in length
located in the upper temporal quadrant 1–3 optic disc
diameters away from the optic disc edge are assessed.
Properties of DVA and its measurement principles
have been previously described in detail [24–26]. The
device allows noninvasive online assessment of vessel
diameter, depending on times and locations along the
vessel. For this purpose, the DVA consists of a retinal
camera (450 FF; Carl Zeiss, Jena, Germany), a digital
camera for electronic online imaging, and a personal
computer for system control, analysis, and recording of
the obtained data. Additionally, each measurement is
recorded on videotape, which provides a possibility for
off-line reassessment of the data. In cases of insufficient
data points in the original assessment, additional
measurements of retinal arterial reaction can be taken
off-line from videotape recordings using DVA.
Electrocardiogram (ECG)
The 24-h 12-lead ECG recordings are recorded using the
Lifecard CF digital Holter recorder (Delmar Reynolds/
Spacelabs, Nuremberg, Germany). ECG and heart rate
variability (HRV) analysis are determined by using
commercial equipment (Delmar Reynolds/Spacelabs
Pathfinder, Nuremberg, Germany) and previously
published technologies by use of customized and validated
software. An experienced physician blinded to the
patient’s clinical status manually reviews and processes all
recordings to obtain the sequence of individual R-R inter-
vals together with beat classification (sinus beat, VPC,
artifact). Besides, automatic annotation of the ECG is
performed for comparison [27]. RR intervals are then
further processed. The 24-h ECG recordings are analyzed
in terms of traditional parameters, such as QT, QTc, PQ
and QRS intervals [28] and left ventricular hypertrophy
(LVH) parameters, such as Sokolow-Lyon Index and
Cornell Index [29]. For the analysis of the variability of R-
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R intervals, several HRV parameters are taken. These
range from traditional parameters in the time and
frequency domain (e.g., standard deviation of the N-N
intervals, total power), over further linear (e.g., Poincare
indices, the triangular index) to non-linear parameters
(e.g., entropy measures, detrended fluctuation analysis)
[30–32]. Furthermore, heart rate turbulence (HRT) and
deceleration capacity (DC) are calculated according to
previously published technologies using established cut-
off values. Briefly, HRT quantifies the baroreflex-mediated
short-term oscillation of the cycle lengths following
ventricular premature complexes [33]. DC quantifies the
mean amplitude of all deceleration-related oscillations of
heart rate observed in the recording period [34] and is
based on a new signal processing algorithm termed phase-
rectified signal averaging (PRSA) which is capable of
extracting periodic components out of non-stationary,
noisy signals [35].
Neurocognitive testing
Cognitive function is measured using the Montreal
Cognitive Assessment (MoCA) [36]. The MoCA is a
short screening instrument for cognitive impairment,
which evaluates the domains attention and concentra-
tion, memory, orientation, language, visuoconstructional
skills, conceptual thinking, calculations and executive
functions. Assessment of the latter function is of particu-
lar importance, because, apart from memory function, it
seems to be impaired early in hemodialysis patients
[37, 38]. Cognitive testing is performed under standard-
ized conditions (before dialysis and alone in a separate
room), as proposed previously [6].
In addition to MoCA, the Clinical Dementia Rating
(CDR) is applied, being the international standard for
evaluation of the overall severity of dementia [39]. The
assessment includes an interview with an informant or
care-giver of the patient, which covers six cognitive and
functional domains: memory, orientation, judgment and
problem solving, community affairs, home and hobbies
and personal care.
Clinical covariates, endpoints, statistical considerations
and data collection
Adjudicated baseline comorbidities
Baseline comorbidity is determined by the ISAR
Endpoint Committee with two independent reviews and
a final review. If a consensus cannot be reached, other
members of the committee review the chart and a
majority vote of the committee determines the final
comorbidity. Comorbidity will be assessed by the ori-
ginal Charlson Comorbidity Index (CCI) [40] and
adapted versions of the CCI for ESRD patients [41–43]
as far as this data is available from the records at
inclusion. Assigned cause of end stage renal disease is
obtained from medical record review, kidney biopsy
reviews if available and interview with the patient at
inclusion.
Adjudicated clinical cardiovascular events and outcomes
Mortality ascertainment The observation period for
each participant begins at enrollment and continues for
72 months after inclusion. Mortality events are docu-
mented from clinic reports, medical records and inter-
views with the physicians in the dialysis centers.
End points We aim at building a combined dataset to
answer questions about the complex and so far only
insufficiently understood pathophysiology behind the
extreme cardiovascular and non-cardiovascular mortality
in dialysis patients. Final goal is the development of a
robust model to predict cardiovascular morbidity and
mortality and death of all causes in a multivariable
Cox-regression analysis. The study end points and serious
adverse events are monitored at the time of the follow-up
examinations at 24 and 72 months and entered in the
study database. Furthermore we will be continuously
informed by the dialysis units of the participants death.
On notification of a death event we will gather all available
clinical information and if in doubt of the correct
diagnosis we will contact the next of kin. A panel of three
physicians comprising a nephrologist and a cardiologist
will independently adjudicate all CV and non CV
outcomes based on medical documentation or interview
with the local dialysis units. All analyses of end points are
based on the following classification by the end-point
committee which has to be agreed on by consensus or
majority vote.
Outcomes Major cardiovascular events are defined as:
1) Sudden cardiac death (SCD) defined as a sudden
pulseless condition out of the hospital (most
probably due to arrhythmia). If the event is
unwitnessed SCD will be suspected if the patient has
been seen stable within the last 24 h preceding the
event.
2) fatal or non-fatal myocardial infarction (MI), defined
as chest pain, dynamic troponin change, cardiogenic
shock and original ECG or ECG report to distin-
guish ST-elevated MI vs. non-ST-elevated MI.
3) need for coronary revascularization (coronary artery
bypass graft/percutaneous coronary
intervention(PCI)/percutaneous transluminal
coronary angioplasty) or death after cardiovascular
procedure/operation (e.g. cardiac valve surgery, PCI)
4) Death or hospitalization due to congestive heart
failure (CHF).
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5) ischemic stroke (defined as an acute focal neurologic
deficit of sudden onset attributed to the occlusion of
a cerebral arterial vessel by a thrombus), non
ischemic-stroke (due to major bleeding)
Major non-cardiovascular, non-cerebrovascular events
are defined as:
1) Death or hospitalization due to infection or sepsis
(pneumonia, urogenital infection, gastrointestinal,
endocarditis, shunt infection, cutaneous infection,
meningitis)
2) Death or hospitalization due to malignancy
3) Death due to chronic lung disease (chronic
obstructive pulmonary disesase (COPD), asthma,
emphysema, pulmonary hypertension)
4) Gastrointestinal death (bleeding, pancreatitis,
malnutrition)
5) Death or hospitalization due to trauma or accident
6) Death or hospitalization due to other causes
Adverse events As the ISAR study is strictly observa-
tional, there are no study related adverse events to be
expected. All pathological examinations that are found
throughout the data acquisition or in the analysis of the
data are immediately communicated to the attending
physicians.
Sample size
It is intended to recruit a number of patients that allows
to detect relevant differences in mortality between
groups of interest and that provides sufficient informa-
tion for development of a multivariable predictive model
for mortality. With an included number of 500 patients,
we expect to observe about 100 deaths within the
follow-up period of 2 years, based on an assumed 2-year
mortality rate of 20 % in our population of dialysis
patients [44]. So the study is sufficiently powered (power
of about 80 %) to detect differences in mortality between
two balanced groups (n = 250 patients per group, if the
true difference in 2-year mortality between the groups is
10 percentage points (25 % vs. 15 %). For a comparison
of two unbalanced groups with sizes of 100 and 400
individuals, e.g. for comparison of groups with presence
and absence of a potential risk factor, a true difference in
2-year mortality of 30 % vs. 17.5 % could be detected
with a probability (=power) of about 80 %. These
differences seem realistic considering reported figures
from recent studies [44, 45].
In order to model the hazard rate using a multivariable
Cox regression model, the number of observed events is
the “limiting sample size” [46]. Based on various simula-
tion studies, the number of predictors that can be
included in a multivariable regression model that is
likely to provide reliable results is assumed to lie within
“limiting sample size divided by 5″ and “limiting sample
size divided by 20” [46–48]. Consequently, with a sample
size of 500 patients leading to an expected number of
100 observed events, about 10 to 15 predictor variables
can be included in a multivariable Cox regression model,
which appears to be an adequate number given possible
candidates and previously proposed prediction models
for mortality in dialysis patients [44].
Statistical analysis
Baseline characteristics are described with mean and
standard deviation for normally distributed continuous
variables, with median and 1st and 3rd quartile for not
normally distributed continuous variables and with
number (%) for categorical data. Statistical testing of
baseline data is performed with the χ2 test for qualitative
variables. Continuous variables are analyzed with
ANOVA and consequent t-tests with correction for
multiple comparisons for normally distributed data. For
not normally distributed data we use Kruskal-Wallis test.
Survival probabilities in the whole study population and
for relevant patient groups will be estimated using the
Kaplan-Meier method. Estimated 2-year survival prob-
abilities and corresponding 95 % confidence intervals
will be presented. Group comparisons will be conducted
using the logrank test and the association between
quantitative measures and risk will be assessed using
Cox proportional hazards models. Hazard ratios with
95 % confidence intervals will be shown. For endpoints
with competing risks, as e.g. death from infection or
death from a cardiovascular event, cumulative incidence
functions will be drawn and cause-specific hazard rates
will be compared or modelled, respectively [49]. All
statistical tests will be performed two-sided on a level of
significance of α = 5 %. Due to the explorative character
of the study no adjustment for multiple testing will be
performed. One main goal of the study is to develop a
prognostic model for the 2 year survival probability.
Various models with different combinations of covariates
will be fit to the data. Assumptions of linearity and
additivity will be checked. Prognostic accuracy of the
model will be assessed using the C index. Resampling
methods (cross-validation, bootstrapping) will be applied
to estimate the model performance in external data and
to identify the best model for prognosis of patient
survival. It is intended to write a more detailed statistical
analysis plan for development of the prognostic model
before the analysis is performed.
Ethical considerations
As this study is strictly observational there are no
adverse events to be expected that are related to the
study. As soon as the study observers find pathological
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results while evaluating the study examinations, the
responsible doctor in the dialysis center will immediately
be informed. Furthermore, 24-h Holter ECG and ABPM
results of all study participants will be handed to the
responsible doctors. There will be no treatment rec-
ommendation from the study investigators. The
complete responsibility for the treatment of the ESRD
patients is in the hands of the responsible doctors in
the dialysis centers.
Data management and privacy protection
The concept, design and execution of the study,
including all data management and analysis are entirely
investigator driven. Statistical and methodological
support is provided from the institute of medical
statistics and epidemiology of the Technical University
of Munich (TUM, IMSE).
Discussion
Within this study we aim to establish an ESRD cohort
which reflects current epidemiology in dialysis centers
worldwide. By measuring multiple cardiovascular
variables of micro- and macrocirculation we hope to
gain further insight into the complex process that finally
leads to an extreme cardiovascular morbidity and
mortality in these patients. The strength of the study is
the chance to combine established risk stratification
parameters like PWV, PWA, autonomic dysfunction,
biomarkers of vascular calcification and inflammation
into a complex model, as there has never been such a
wide array of examinations in a single study.
ABPM and pulse wave analysis
Ambulatory and office/dialysis blood pressure monitoring
(ABPM)
ABPM is the gold standard for diagnosis of hypertension
to identify white coat hypertension, masked hyperten-
sion and nocturnal hypertension which has been stated
in recent guidelines [50, 51]. In dialysis patients this
method is usually only rarely performed (despite hyper-
tension being one of the leading causes of ESRD)
because the BP monitoring while the patient is in the
dialysis unit (peridialysis blood pressure) is trusted. In
many dialysis centers it is common practice to measure
only pre and post dialysis values for SBP and DBP. With
these values antihypertensive therapy is refined. Without
a doubt the use of out of dialysis blood pressure
measurement or even better ABPM does shape a much
clearer picture of true BP but due to expenses and
unwillingness of the patients this examination is not
routinely performed. There is clear evidence that there is
a u-shaped curve of mortality in relation to systolic
blood pressure [52–54]. This non-monotonic relation-
ship has also been recognized for other risk factors like
nutrition and lipid metabolism in ESRD patients. As
ABPM has not entered any guidelines for the diagnosis
of hypertension in dialysis patients and the value of
ABPM itself in ESRD is not established and still debated
by experts [55–57], we hope to gain further insight in
the feasibility and usefulness of ABPM in ESRD patients.
Pulse wave analysis/central hemodynamics
Arterial stiffness as a sign of vascular calcification is a
hallmark finding in patients with chronic kidney disease
and especially end stage renal disease patients [58].
Estimation of vascular calcification can be performed
either directly by imaging coronary calcification [59] or
indirectly by monitoring arterial stiffness by (1) deter-
mining pulse wave velocity [60] by measuring pressure
wave at two sites (common carotid and femoral artery)
and calculation of the time delay of both pressure curves
or by means of (2) pulse wave analysis where the
brachial pulse wave is mathematically transferred into an
aortic pulse wave which can be used to derive PWV
values in m/s [10, 61]. The huge advantage of using the
latter method is the chance to use 24-h pulse wave
analysis and not only a single measurement [10]. This is
especially important as pulse wave curves change with
volume shifts during and in the period after the dialysis
procedure [13]. This method has been very well vali-
dated in the last years not only in normal subjects [10]
and cardiovascular risk cohorts [11, 62] but also in CKD
[18] and dialysis patients [13]. Another advantage is the
user independency of the method which would allow
broad application in dialysis centers, because “classical”
measurement of PWV needs an experienced examiner
and is time consuming. Therefore, PWV measurement
has not entered clinical routine use except in specialized
academic centers within study protocols.
Static and dynamic retinal vessel analysis (RVA)
Retinal microvasculature is easily accessible with non-
invasive imaging techniques and allows visualization of
the systemic microcirculation without the need of, e.g.,
gluteal subcutaneous fat biopsy [63] or estimation of
microalbuminuria which is impossible in dialysis
patients without residual renal function. It has been
shown that chronic kidney disease (CKD) associates with
arteriolar narrowing [64], but so far there is only very
limited information on the retinal vessels in dialysis
patients [65]. Despite macrovacular disease we know
that microvascular disease contributes significantly to
the development of renal failure. By acquiring digital
images and extracting quantitative values for retinal
caliber values of the arteriolar and venous bed we are
able to look for associations with traditional and non-
traditional risk factors and renal disease. Besides, we get
a clearer picture of the complex vascular changes in
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both micro- and macrocirculation and the interplay
between these two closely connected systems.
Electrocardiogram (ECG)
Cardiovascular disease accounts for 50 % of deaths in
dialysis patients [3]. Sudden cardiac death (SCD) is with
50 % the most common cause of cardiovascular death.
Other reasons are coronary artery disease (CAD),
congestive heart failure (CHF), valvular heart disease
and atrial fibrillation (AF). The prevalence of atrial fibril-
lation has risen in ESRD patients and is associated with
higher mortality rates in this subgroup of patients [66].
In recent years analysis of cardiac autonomic dysfunc-
tion has helped to improve risk stratification in patients
after a myocardial infarction [33–35]. It has also been
shown that cardiac autonomic dysfunction is a good pre-
dictor for cardiovascular mortality in CKD and ESRD
patients [67, 68]. Furthermore, there is the possibility of
cross-analysis of other biosignals like pulsewaves along
with the ECG signals [69]. Therefore, we added this easy,
non-invasive and operator-independent method to the
set of technical procedures in our study.
Neurocognitive testing
The profile of dialysis patients has changed significantly
in the last years [2]. Today patients on dialysis are older
and show more comorbidities than a decade ago.
Undoubtedly, the comorbidity of cognitive impairment
has grown as well and health care providers are more
and more faced with the treatment of cognitive impair-
ment and also with the decision if patients are still able
and willing to adhere to medical prescriptions and the
recommended dialysis treatments. The estimated preva-
lence of cognitive impairment in dialysis patients of age
55 and older (the major age group of dialysis patients) is
reported with up to 70 % [70] and therefore we need a
better understanding of the pathophysiology behind the
cognitive decline, its relation to vascular changes and
dialysis and non-dialysis dependent risk factors and its
longitudinal time course. Within this study we could
associate cognitive impairment scores with the diverse
vascular parameters described above and in more detail
below. Therefore, we decided to include a subgroup of
patients with the simple and in dialysis patients validated
Montreal cognitive Assessment (MoCA) Score [36, 71]
and Clinical Dementia Rating Scale (CDR) [39] at
different time points.
Conclusion
Within this study we aim to establish an ESRD cohort
which reflects current epidemiology in dialysis centers in
Germany and might help to get a better understanding
of the pathophysiology driving mortality and morbidity
in ESRD. We hope to improve risk stratification by
establishing a multivariable Cox regression model with a
combination of the parameters studied in the cohort.
We sought to design a feasible protocol combining
examinations which are easy to perform and mainly
user-independent to assure unbiased quality of data. The
ISAR study has already finished recruiting patients and
is in the process of follow up examinations. We are keen
to present first data of the baseline examinations after
database lock.
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